Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03PKJ
|
|||
| Former ID |
DIB008647
|
|||
| Drug Name |
MK-6186
|
|||
| Synonyms |
MK-6186; UNII-K3978U665M; 1034474-19-5; K3978U665M; MK 6186; SCHEMBL2878768; CHEMBL1939499; FZBAOOQVQXATRL-UHFFFAOYSA-N; ZINC73240561; DB12999; DA-16093; 3-(1-((1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-5-chloro-1H-indazol-4-yloxy)-5-chlorobenzonitrile; FT-0726721; 3-((1-((2H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-5-chloro-1H-indazol-4-yl)oxy)-5-chlorobenzonitrile; 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4- b]pyridin-3-ylmethyl)-1H-indazol-4-yl]oxy}benzonitrile
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
Merck & Co Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H12Cl2N6O
|
|||
| Canonical SMILES |
C1=CC2=C(NN=C2N=C1)CN3C4=C(C=N3)C(=C(C=C4)Cl)OC5=CC(=CC(=C5)C#N)Cl
|
|||
| InChI |
1S/C21H12Cl2N6O/c22-13-6-12(9-24)7-14(8-13)30-20-16-10-26-29(19(16)4-3-17(20)23)11-18-15-2-1-5-25-21(15)28-27-18/h1-8,10H,11H2,(H,25,27,28)
|
|||
| InChIKey |
FZBAOOQVQXATRL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1034474-19-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01152255) MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2). U.S. National Institutes of Health. | |||
| REF 2 | Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.